 BriaCell Therapeutics Corp NASDAQ: BCTX has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation NASDAQ: INCY. The Phase 12a combination study will evaluate BriaCells lead candidate, Bria-IMT, with Incytes retifanlimab epacadostat to treat advanced breast cancer. 